UnknownPhase 4

Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease

China40 participantsStarted 2012-01

Plain-language summary

The investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable IPA underlying chronic obstructive pulmonary disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Proven invasive pulmonary aspergillosis * Probable invasive pulmonary aspergillosis * Hospitalized in respiratory wards * Not having received an empirical antifungal therapy for 72h before inclusion Exclusion Criteria: * A history of allergy to echinocandins * Severe renal failure, severe hepatic insufficiency * Inadequately treated bacterial infection * Documented HIV infection * Status of pregnancy or lactation

What they're measuring

Global response (defined as both clinical and microbiologic success) at the end of intravenous therapy

Timeframe: At end of intravenous treatment(three week)

Trial details

NCT IDNCT01499433

SponsorThe First Affiliated Hospital of Guangzhou Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-09

Contact for this trial

Feng Ye, MD

862083062836 yefeng@gird.cn

View on ClinicalTrials.gov More Invasive Pulmonary Aspergillosis trials